Pacific Shuanglin Bio-pharmacy Co., LTD

Informe acción SZSE:000403

Capitalización de mercado: CN¥16.6b

Pacific Shuanglin Bio-pharmacy Crecimiento futuro

Future controles de criterios 2/6

Pacific Shuanglin Bio-pharmacy is forecast to grow earnings and revenue by 13.3% and 15% per annum respectively. EPS is expected to grow by 13.2% per annum. Return on equity is forecast to be 10.9% in 3 years.

Información clave

13.3%

Tasa de crecimiento de los beneficios

13.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs44.8%
Tasa de crecimiento de los ingresos15.0%
Rentabilidad financiera futura10.9%
Cobertura de analistas

Good

Última actualización29 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

If EPS Growth Is Important To You, Pacific Shuanglin Bio-pharmacy (SZSE:000403) Presents An Opportunity

Oct 10
If EPS Growth Is Important To You, Pacific Shuanglin Bio-pharmacy (SZSE:000403) Presents An Opportunity

Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Shares May Have Run Too Fast Too Soon

Aug 16
Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Shares May Have Run Too Fast Too Soon

We Think Pacific Shuanglin Bio-pharmacy (SZSE:000403) Can Stay On Top Of Its Debt

Jul 22
We Think Pacific Shuanglin Bio-pharmacy (SZSE:000403) Can Stay On Top Of Its Debt

Is Now The Time To Put Pacific Shuanglin Bio-pharmacy (SZSE:000403) On Your Watchlist?

May 24
Is Now The Time To Put Pacific Shuanglin Bio-pharmacy (SZSE:000403) On Your Watchlist?

Previsiones de crecimiento de beneficios e ingresos

SZSE:000403 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20263,9131,070N/A1,0506
12/31/20253,431922N/A8796
12/31/20242,856778N/A7123
9/30/20242,844829311681N/A
6/30/20242,756796286635N/A
3/31/20242,504678134521N/A
12/31/20232,329612302679N/A
9/30/20232,28756438473N/A
6/30/20232,12350911452N/A
3/31/20232,166538142553N/A
1/1/20232,405587146524N/A
9/30/20222,123437155477N/A
6/30/20222,172436246532N/A
3/31/20222,187440118459N/A
1/1/20221,97239182408N/A
9/30/20211,730386219465N/A
6/30/20211,413299198400N/A
3/31/20211,12421786174N/A
1/1/20211,050186155195N/A
9/30/2020937137-4123N/A
6/30/2020941146-1047N/A
3/31/2020949161213255N/A
1/1/2020916160150191N/A
9/30/2019867127131166N/A
6/30/201983591115152N/A
3/31/20198197676111N/A
1/1/20198608082117N/A
9/30/2018805603266N/A
6/30/201879144N/A18N/A
3/31/201877130N/A0N/A
12/31/201768522N/A-15N/A
9/30/201765234N/A-7N/A
6/30/201760052N/A-11N/A
3/31/201753052N/A1N/A
12/31/201656150N/A62N/A
9/30/201654568N/A40N/A
6/30/201652766N/A50N/A
3/31/201655481N/A69N/A
12/31/201550078N/A70N/A
9/30/201556870N/A119N/A
6/30/201558775N/A107N/A
3/31/201551332N/A99N/A
12/31/2014489123N/A77N/A
9/30/2014403105N/A78N/A
6/30/2014393118N/A114N/A
3/31/2014444149N/A83N/A
12/31/201347870N/A91N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 000403's forecast earnings growth (13.3% per year) is above the savings rate (2.9%).

Beneficios vs. Mercado: 000403's earnings (13.3% per year) are forecast to grow slower than the CN market (25.8% per year).

Beneficios de alto crecimiento: 000403's earnings are forecast to grow, but not significantly.

Ingresos vs. Mercado: 000403's revenue (15% per year) is forecast to grow faster than the CN market (14% per year).

Ingresos de alto crecimiento: 000403's revenue (15% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 000403's Return on Equity is forecast to be low in 3 years time (10.9%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y